Pharma Focus Asia

Parse Biosciences Announces Partnership with Molecular Diagnostics Korea

Tuesday, June 07, 2022

Parse Biosciences, a leading provider of scalable single-cell sequencing solutions, today announced a partnership with Molecular Diagnostics Korea (MDxK) that will expand its presence in Asia by providing its entire line of Evercode™ Whole Transcriptome products as well as Cell and Nuclei Fixation kits in South Korea.

MDxK provides instruments, consumables, and various services to support molecular research. The company’s specialization in areas of multi-omics, biologics, crystallography, and bio-banking has led to its status as a premier supplier of research tools with superior outcomes.

The partnership comes shortly after the announcement of Parse Biosciences’ $41.5M Series B round in February 2022, which is enabling the company to expand commercialization of its single-cell RNA-Seq products in response to growing demand. It further provides distribution support for the expanding product portfolio, which includes applications in immune profiling, chromatin profiling, CRISPR screens, and targeted gene panels. The Parse Biosciences approach to single-cell sequencing is based on the Evercode technology, a patented technique of split-pool combinatorial barcoding that enables researchers to sequence cells at scale without the need for expensive lab equipment.

“We are working hard to bring simpler, more scalable, and affordable solutions to researchers, regardless of location,” said Alex Rosenberg, CEO and Co-founder of Parse Biosciences. “We are thrilled to partner with MDxK to broaden access to our technology and support the growing single-cell sequencing community worldwide.”

“We are very pleased to work with Parse Biosciences and proud of providing such advanced technology to the rapidly growing single-cell research field,” said MDxK CEO SungBo Shim. “We believe these scalable solutions give researchers broader and deeper biological insight with more cost effectiveness.”

Access to the Parse Biosciences technology has grown rapidly since the commercial availability of its products in 2021. Since expanding beyond North America to Europe, Australia, New Zealand, and Southeast Asia, Parse is now used in over 300 labs across the globe.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024